Ligand Pharmaceuticals Inc. Announces Presentation of Data from Multiple Studies of Dinaciclib by its Partner Merck at the American Society of Hematology Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that multiple clinical studies of dinaciclib (SCH 727965) will be presented by Merck at the upcoming 52nd American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida at the Orange County Convention Center, December 4–7, 2010.